Matches in SemOpenAlex for { <https://semopenalex.org/work/W4249194881> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W4249194881 endingPage "881" @default.
- W4249194881 startingPage "876" @default.
- W4249194881 abstract "Abstract Thirty-four adults with refractory acute lymphocytic leukemia received salvage therapy with mitoxantrone 5 mg/m2 intravenously over 1 hour daily for 5 days and cytosine arabinoside (ara-C) 3 g/m2 intravenously over 2 hours every 12 hours for six doses, followed by granulocyte- macrophage colony-stimulating factor (GM-CSF) 125 microgram/m2 intravenously over 4 hours daily until recovery of granulocytes above 2.0 x 10(3)/microL. Their outcome was compared with 29 prognostically similar historical control patients treated with the identical chemotherapy without GM-CSF. Overall, the complete response rates were similar in the treatment and control groups (13 of 34 [38%] v 11 of 29 [38%]). There was a trend for less remission induction mortality in the GM-CSF-treated patients (2 of 34 [6%] v 6 of 29 [21%]; P = .08), but, conversely, a higher rate of resistant disease (19 of 34 [56%] v 10 of 29 [34%]; P = .09). Recovery of granulocyte counts above 500/microL was significantly faster in the GM-CSF-treated group (25 days v 33 days; P less than .01), but there was no reduction in the incidence of febrile episodes (91% v 93%) or of documented infections (59% v 59%). Survival was prolonged in the GM-CSF-treated patients but was not of clinical relevance (31 v 20 weeks; P = .05). In summary, the addition of GM-CSF to intensive chemotherapy in refractory adult ALL was associated with a reduction in the remission induction mortality, probably secondary to a shorter duration of granulocytopenia, but not with an improvement in complete response rates." @default.
- W4249194881 created "2022-05-12" @default.
- W4249194881 creator A5007152490 @default.
- W4249194881 creator A5014987595 @default.
- W4249194881 creator A5030171128 @default.
- W4249194881 creator A5048402617 @default.
- W4249194881 creator A5050091658 @default.
- W4249194881 creator A5063282789 @default.
- W4249194881 creator A5077488440 @default.
- W4249194881 creator A5090554156 @default.
- W4249194881 date "1992-02-15" @default.
- W4249194881 modified "2023-10-17" @default.
- W4249194881 title "Intensive chemotherapy with mitoxantrone and high-dose cytosine arabinoside followed by granulocyte-macrophage colony-stimulating factor in the treatment of patients with acute lymphocytic leukemia" @default.
- W4249194881 doi "https://doi.org/10.1182/blood.v79.4.876.876" @default.
- W4249194881 hasPublicationYear "1992" @default.
- W4249194881 type Work @default.
- W4249194881 citedByCount "2" @default.
- W4249194881 crossrefType "journal-article" @default.
- W4249194881 hasAuthorship W4249194881A5007152490 @default.
- W4249194881 hasAuthorship W4249194881A5014987595 @default.
- W4249194881 hasAuthorship W4249194881A5030171128 @default.
- W4249194881 hasAuthorship W4249194881A5048402617 @default.
- W4249194881 hasAuthorship W4249194881A5050091658 @default.
- W4249194881 hasAuthorship W4249194881A5063282789 @default.
- W4249194881 hasAuthorship W4249194881A5077488440 @default.
- W4249194881 hasAuthorship W4249194881A5090554156 @default.
- W4249194881 hasBestOaLocation W42491948811 @default.
- W4249194881 hasConcept C126322002 @default.
- W4249194881 hasConcept C142424586 @default.
- W4249194881 hasConcept C203014093 @default.
- W4249194881 hasConcept C2776694085 @default.
- W4249194881 hasConcept C2776863199 @default.
- W4249194881 hasConcept C2777478134 @default.
- W4249194881 hasConcept C2777767877 @default.
- W4249194881 hasConcept C2778041864 @default.
- W4249194881 hasConcept C2778461978 @default.
- W4249194881 hasConcept C2778690821 @default.
- W4249194881 hasConcept C2780923524 @default.
- W4249194881 hasConcept C2781107101 @default.
- W4249194881 hasConcept C2909962599 @default.
- W4249194881 hasConcept C71924100 @default.
- W4249194881 hasConcept C86803240 @default.
- W4249194881 hasConcept C87355193 @default.
- W4249194881 hasConcept C90924648 @default.
- W4249194881 hasConceptScore W4249194881C126322002 @default.
- W4249194881 hasConceptScore W4249194881C142424586 @default.
- W4249194881 hasConceptScore W4249194881C203014093 @default.
- W4249194881 hasConceptScore W4249194881C2776694085 @default.
- W4249194881 hasConceptScore W4249194881C2776863199 @default.
- W4249194881 hasConceptScore W4249194881C2777478134 @default.
- W4249194881 hasConceptScore W4249194881C2777767877 @default.
- W4249194881 hasConceptScore W4249194881C2778041864 @default.
- W4249194881 hasConceptScore W4249194881C2778461978 @default.
- W4249194881 hasConceptScore W4249194881C2778690821 @default.
- W4249194881 hasConceptScore W4249194881C2780923524 @default.
- W4249194881 hasConceptScore W4249194881C2781107101 @default.
- W4249194881 hasConceptScore W4249194881C2909962599 @default.
- W4249194881 hasConceptScore W4249194881C71924100 @default.
- W4249194881 hasConceptScore W4249194881C86803240 @default.
- W4249194881 hasConceptScore W4249194881C87355193 @default.
- W4249194881 hasConceptScore W4249194881C90924648 @default.
- W4249194881 hasIssue "4" @default.
- W4249194881 hasLocation W42491948811 @default.
- W4249194881 hasOpenAccess W4249194881 @default.
- W4249194881 hasPrimaryLocation W42491948811 @default.
- W4249194881 hasRelatedWork W19185866 @default.
- W4249194881 hasRelatedWork W19219843 @default.
- W4249194881 hasRelatedWork W21619 @default.
- W4249194881 hasRelatedWork W2682204 @default.
- W4249194881 hasRelatedWork W2786776 @default.
- W4249194881 hasRelatedWork W4351535 @default.
- W4249194881 hasRelatedWork W4406366 @default.
- W4249194881 hasRelatedWork W4479156 @default.
- W4249194881 hasRelatedWork W5279832 @default.
- W4249194881 hasRelatedWork W6531846 @default.
- W4249194881 hasVolume "79" @default.
- W4249194881 isParatext "false" @default.
- W4249194881 isRetracted "false" @default.
- W4249194881 workType "article" @default.